



You are  
invited  
to



## 2<sup>nd</sup> Annual Biosimilars Forum

***Statistical and Regulatory Perspectives  
in Bio- and Nanosimilar Development***

### **Focus on the most actual challenges of biosimilar development**

This unique forum will cover important issues and specific areas of debate facing clinical development teams biosimilars with a strong scientific focus on statistical and regulatory perspectives. It is particularly useful for those who are interested in constructive and open dialogue between medical statisticians, regulatory professionals, clinical researchers and sponsors with whom they collaborate.



**5 – 6 OCTOBER, 2017**



**Budapest**

## The 2<sup>nd</sup> annual event with participation of scientific experts and prominent professionals from the field of clinical research

This two-day series of events – a continuation of the very successful 1st Annual Biosimilar Forum from last year – consists of a **course day** (scheduled for October 5th) and a **professional symposium** (invited presentations and round table session, scheduled for October 6th) regarding hot topics related to the development of biosimilars.

### SCIENTIFIC PROGRAMME COMMITTEE



**Ildikó ARADI**

Head of Clinical Development of Biologics, Gedeon Richter Plc; Vice-Chair, Medicines for Europe, Biosimilar Medicines Group



**Bernd JILMA**

Vice Chair, Department Clinical Pharmacology, Medical University of Vienna



**Franz KÖNIG**

Associate Professor, Medical University of Vienna, Section for Medical Statistics



**Stephan LEHR**

Statistician, Austrian Medicines and Medical Devices Agency; President, Viennese Section of IBS



**Julia SINGER**

Chief Scientific Officer, Accelsiors; President, Hungarian Society for Clinical Biostatistics



**Vid STANULOVIC**

Consultant, Clinical Development and Pharmacovigilance

### KEYNOTE PRESENTATIONS

#### 12 years of biosimilars in Europe:

*What is the exposure and response in our learning curve?*



**Andrea LASLOP**

Unit Head, Austrian Medicines and Medical Devices Agency

#### Immune side effects of biologicals and nanomedicines: *unsolved issues in bio- and nanosimilar development*



**János SZEBENI**

Director of the Nanomedicine Research and Education Center, Semmelweis Medical University, Budapest

### ORGANIZERS



Viennese Section of the International Biometric Society



Hungarian Society for Clinical Biostatistics

## SPEAKERS:



**László ENDRÉNYI**  
Professor Emeritus of Pharmacology and  
Biostatistics, University of Toronto;



**Helmut SCHÜTZ**  
Owner at BEBAC – Consultancy Services for  
Bioequivalence and Bioavailability Studies



**Andrea LASLOP**  
Unit head, Austrian Medicines and  
Medical Devices Agency



**Bernd JILMA**  
Vice Chair, Department Clinical  
Pharmacology, Medical University of Vienna



**Stephan LEHR**  
Biostatistician, Austrian Medicines and Medical  
Devices Agency, President, Viennese Section of  
IBS



**Johanna MIELKE**  
Biostatistician, Novartis Pharma AG



**Ina-Christine RONDAK**  
Biostatistician, Seconded National Expert from  
Klinikum rechts der Isar of Technische  
Universität München to EMA;



**János SZEBENI**  
Director of the Nanomedicine Research and  
Education Center, Semmelweis Medical  
University, Budapest,



**László TÓTFALUSI**  
Associate Professor, Faculty of Pharmacology,  
Semmelweis Medical University, Budapest

LEARN MORE at the website of the event!



[www.biosimsforum.com](http://www.biosimsforum.com)

## AGENDA:

### 1st day: COURSES with special lecturers



5<sup>th</sup> OCT, 2017

11:00 - 12:00 | Registration

12:00 - 13:00 | Scientific factors in biosimilar product development | Presented by: **László Endrényi**

13:00 - 14:00 | Lunch break

14:00 - 17:40 | Open issues in the assessment of bioequivalence and biosimilarity

| The course is lectured by: **Helmut Schütz**

#### Main topics of the Course:

- Unequal carry-over – “solved” in BE but still an Issue in Assessing Biosimilarity?
- Multi-Group and Multi-Site Studies. To pool or not to pool?
- Group-Sequential and Two-Stage Designs.
- Reference-scaling and Control of the Type I Error.

#### Schedule of the course:

- 14:00 - 15:00 | 1st part of COURSE
- 15:00 - 15:20 | Coffee break: refreshments & networking
- 15:20 - 16:20 | 2nd part of COURSE
- 16:20 - 16:40 | Coffee break
- 16:40 - 17:40 | 3rd part of COURSE

17:40 - 18:00 | Discussion

# AGENDA

2nd day: **SYMPOSIUM and ROUND TABLE**




6<sup>th</sup> OCT, 2017

9:00 - 9:30	<b>Registration</b> (for those attending only day 2)
9:30 - 10:00	<b>Clinical trials for biosimilars in Europe: an updated systematic comparison of the clinical development programs</b>   Presented by: <i>Johanna Mielke</i>
10:00 - 10:30	<b>Algorithms for evaluating reference scaled average bioequivalence: power, bias and consumer risk</b>   Presented by: <i>László Tóthfalusi, László Endrényi</i>
10:30 - 11:00	<b>Investigating PK/PD in the steep ascending part of the dose response curve</b>   Presented by: <i>Bernd Jilma</i>
11:00 - 11:30	<b>Coffee Break</b>
11:30 - 12:20	<b>1<sup>st</sup> Keynote lecture: 12 years of biosimilars in Europe: what's the exposure and response in our learning curve?</b>   Presented by: <i>Andrea Laslop</i>
12:20 - 12:50	<b>Regulatory perspective on comparison of quality attributes in drug development</b>   Presented by: <i>Ina-Christine Rondak, Stephan Lehr</i>
12:50 - 13:45	<b>Lunch Break</b>
13:45 - 14:25	<b>2<sup>nd</sup> Keynote lecture: Immune side effects of biologicals and nanomedicines: unsolved issues in bio- and nanosimilar development</b>   Presented by: <i>János Szebeni</i>
14:25 - 14:45	<b>Coffee Break</b>
14:45 - 16:45	<b>Round table discussion</b> Moderator: <i>Júlia Singer</i> (Chief Scientific Officer, Accelsiors Ltd.) Discussants: <ul style="list-style-type: none"> <li>Regulatory perspective: <b>Stephan Lehr</b> (Biostatistician, Austrian Medicines and Medical Devices Agency)</li> <li>Industry perspective: <b>Heike Wöhling</b> (Head of Biostatistics, Sandoz Biopharmaceuticals)</li> </ul> Panel members: <ul style="list-style-type: none"> <li><b>Ildikó Aradi</b> (Head of Clinical Development of Biologics, Gedeon Richter Plc., Vice-Chair, European Generic medicines Association - European Biosimilars Group)</li> <li><b>Bernd Jilma</b> (Vice Chair, Department Clinical Pharmacology, Medical University of Vienna)</li> <li><b>Franz König</b> (Associate Professor, Medical University of Vienna, Section for Medical Statistics)</li> <li><b>Andrea Laslop</b> (Unit Head, Austrian Medicines and Medical Devices Agency)</li> <li><b>Johanna Mielke</b> (Biostatistician, Novartis Pharma AG)</li> <li><b>Vid Stanulovic</b> (Consultant, Clinical Development and Pharmacovigilance)</li> </ul>



## LOCATION OF THE EVENT



## REGISTRATION FEES

- Two-day event: 300 Euros
- 1<sup>st</sup> day course only: 250 Euros
- 2<sup>nd</sup> day only: 100 Euros

WBS and ISCB members can attend the 2<sup>nd</sup> day symposium **for free**.

## REGISTRATION DEADLINE

Please fill in the **Registration Form** on the webpage of the event and send us before

**25<sup>th</sup> September 2017**

- Website: [www.biosimsforum.com](http://www.biosimsforum.com)
- Contact: [event@accelsiors.com](mailto:event@accelsiors.com)

## About the 1<sup>st</sup> Biosimilars Forum (2016)



The very successful 1<sup>st</sup> Annual Biosimilars Forum was hosted in Budapest in the October of the last year by Accelsiors CRO with participation of international scientific experts such as *Shein-Chung Chow* (Professor of Duke University School of Medicine), *Prof Dr. László Endrényi* (Professor Emeritus of University of Toronto), and clinicians, statisticians and regulatory representatives gathered together from around the world to share with each other their perspectives on this hot topic of research in lectures and informal discussions. We had a successful and professionally fruitful event together, at its end the organizers expressed their intention to continue the series. Join us at Budapest in 5-6 of October, 2017 to continue this tradition!